Home/Sponsors Directory

Incyte Corporation

Expanded Access Intelligence

Active EAPs on ClinicalTrials.gov

Score contribution: 60 — 3 supporting sources.

Score 603 references
Featured Reference
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)Opens in new window

Conditions: Squamous Cell Carcinoma of the Anal Canal

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) DiseaseSource

Conditions: STAT1 Gain-of-Function Disease

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)Source

Conditions: Chronic Graft Vs. Host Disease

Past EAPs on ClinicalTrials.gov

Score contribution: 40 — 7 supporting sources.

Score 407 references
Featured Reference
Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic CancerOpens in new window
Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHDSource

Conditions: Graft-versus-host Disease (GVHD)

Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic AnemiaSource

Conditions: Aplastic Anemia

Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell CarcinomaSource
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantSource

Conditions: Graft-versus-host Disease (GVHD)

Expanded Access Use of INCB052793 to Treat a Single Patient With MyelofibrosisSource

Partner with Right2Hope

Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.

Talk to Our TeamExplore Programs